title: The ongoing pursuit of a prophylactic HSV vaccine.
abstract: HSV is among the most common human pathogens in the world. It is known to cause painful, persistent skin lesions, while also being the most common cause of fatal non-epidemic encephalitis as well as the leading cause of corneal blindness. The development of prophylactic vaccines could substantially reduce global health problems associated with HSV. So far, HSV vaccine strategies have shown noticeable efficacy in early development during preclinical phases but remained unsuccessful or unproven in human trials. New understanding of how the immune system mounts a defence against HSV offers practical strategies for vaccine development. A number of promising vaccine candidates are currently awaiting clinical development or already undergoing clinical testing. Therefore, this is a suitable time to assess the progress of HSV vaccine development and consider existing challenges and future improvements needed to achieve an effective prophylactic HSV vaccine.
authors.affiliation: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, M5S 3M2, Canada. erin.chung@utoronto.ca
authors.forename: Erin
authors.initials: E
authors.lastname: Chung
authors.forename: Jonathan
authors.initials: J
authors.lastname: Sen
mesh_terms: D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends*; D006561:Herpes Simplex / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans
chemical_list: D022301:Herpes Simplex Virus Vaccines